Plasma biomarkers, such as Aβ 42/40 ratio and phosphorylated -tau (p-tau) levels have recently had a significant impact on research in the field of Alzheimer’s disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.